Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced the appointment of Dr. Ken Kramer, PhD, as senior vice president of medical affairs, effective immediately.
Kramer brings more than 20 years of neuroscience-focused medical affairs leadership, including roles at Bristol Myers Squibb, Karuna Therapeutics, and AbbVie. He is expected to support Helus in advancing its pipeline and strengthening engagement with clinical and scientific stakeholders.
Helus Pharma, the commercial operating name of Cybin Inc. founded in 2019, is committed to developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s proprietary NSAs are intended to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004, also a proprietary NSA, is in Phase 2 for generalized anxiety disorder. Helus Pharma has an extensive research portfolio of investigational NSAs and operates in Canada, the United States, the United Kingdom, and Ireland.
The company aims to improve the treatment landscape through the introduction of NSAs intended to provide durable improvements in mental health through what it describes as “class leading data.” Helus Pharma trades on NASDAQ under the ticker HELP and on the Cboe CA under the same symbol.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110992889/Tinygemsbreaks-Helus-PharmaTM-NASDAQ-HELP-Cboe-CA-HELP-Appoints-Dr-Ken-Kramer-SVP-Medical-Affairs